| __timestamp | Eli Lilly and Company | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 35942000 |
| Thursday, January 1, 2015 | 6533000000 | 40028000 |
| Friday, January 1, 2016 | 6452000000 | 45853000 |
| Sunday, January 1, 2017 | 6588100000 | 53816000 |
| Monday, January 1, 2018 | 5975100000 | 60804000 |
| Tuesday, January 1, 2019 | 6213800000 | 77252000 |
| Wednesday, January 1, 2020 | 6121200000 | 45736000 |
| Friday, January 1, 2021 | 6431600000 | 50323000 |
| Saturday, January 1, 2022 | 6440400000 | 143526000 |
| Sunday, January 1, 2023 | 6941200000 | 149182000 |
| Monday, January 1, 2024 | 8593800000 | 154335000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Eli Lilly and Company, a stalwart in the sector, has consistently maintained high Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking in 2023 with a 5% rise from the previous year.
Conversely, Halozyme Therapeutics, Inc., a smaller player, has demonstrated a more volatile trend. Notably, from 2021 to 2023, Halozyme's SG&A expenses surged by over 200%, reflecting strategic investments in growth and expansion.
This comparison highlights the contrasting financial strategies of a well-established giant and an emerging innovator. As the industry evolves, these insights provide a window into how companies allocate resources to maintain competitiveness and drive innovation.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.